Peptide Therapy for Gut Health: From IBS to Intestinal Permeability

The gastrointestinal tract is both the largest endocrine organ in the body and one of the most peptide rich environments in human physiology. The gut produces dozens of endogenous peptide hormones, including GLP 1, GLP 2, peptide YY, cholecystokinin, secretin, motilin, and ghrelin, that regulate everything from appetite and digestion to intestinal growth and immune function. Given that context, it is perhaps unsurprising that peptide based therapies show particular promise for gastrointestinal conditions.

BPC 157 is a synthetic pentadecapeptide described as stable in human gastric juice, and its most extensively studied effects relate to gastrointestinal protection and healing (Sikiric et al., 2011, Curr Pharm Des; PMID: 21548867). In rat models, BPC 157 has shown protective and healing effects across a range of GI injuries (Sikiric et al., 2011, Curr Pharm Des; PMID: 21548867). In rat models, it showed prominent protective effects against alcohol induced and NSAID induced gastrointestinal lesions (Sikiric et al., 2011, Curr Pharm Des; PMID: 21548867). In animal studies, the proposed mechanisms include promotion of angiogenesis through VEGFR2 signalling, nitric oxide synthesis via the Akt-eNOS axis, and anti-inflammatory and cytoprotective effects in gastrointestinal and musculoskeletal tissue (McGuire et al., 2025, Curr Rev Musculoskelet Med; PMID: 40789979). In rat colitis models, including cysteamine induced colitis, BPC 157 has been reported to heal colonic lesions (Klicek et al., 2013, J Physiol Pharmacol; PMID: 24304574). In rat studies, it improved healing of a variety of intestinal anastomoses (Bajramagic et al., 2024, Pharmaceuticals (Basel); PMID: 39204186). And it reduced esophagitis and restored lower esophageal sphincter pressure in rat models (Sikiric et al., 2011, Curr Pharm Des; PMID: 21548867). The critical caveat remains: while the preclinical data is extensive, published human clinical data for BPC 157 are very limited (Vasireddi et al., 2025, HSS J; PMID: 40756949). BPC 157 (as PL 14736) has been described as safe in inflammatory bowel disease clinical trials, but peer reviewed efficacy results from those trials are scarce (Sikiric et al., 2011, Curr Pharm Des; PMID: 21548867).

Larazotide acetate (AT 1001) takes a different approach to gut health by targeting the tight junctions between intestinal epithelial cells (Leffler et al., 2015, Gastroenterology; PMID: 25683116). These tight junctions are the gatekeepers of intestinal permeability. When they malfunction, the result is increased paracellular permeability (colloquially called "leaky gut"), which allows bacterial products, undigested food antigens, and inflammatory mediators to cross the intestinal barrier and enter the systemic circulation. Larazotide is a synthetic octapeptide derived from Vibrio cholerae zonula occludens toxin (Zot). Larazotide acts as a zonulin antagonist, intended to prevent pathological opening of tight junctions (Troisi et al., 2021, Curr Med Chem; PMID: 33397225). Zonulin, identified as pre haptoglobin 2 by Alessio Fasano's group, is an endogenous protein that modulates tight junction permeability, and its levels are elevated in celiac disease, type 1 diabetes, and other autoimmune conditions (Fasano, 2011, Physiological Reviews; PMID: 21248165). In a randomized controlled trial, the lowest dose of larazotide (0.5 mg) reduced gastrointestinal symptoms, including abdominal pain, in celiac patients with persistent symptoms despite a gluten free diet, though higher doses were no better than placebo (Leffler et al., 2015, Gastroenterology; PMID: 25683116). In a Phase IIb trial, the lowest dose reduced symptoms in patients on a gluten-free diet (Leffler et al., 2015, Gastroenterology; PMID: 25683116), but the Phase III CeDLara trial was stopped in 2022 after an interim analysis found it unlikely to meet its goal. Larazotide is notable as one of the few therapies targeting intestinal permeability that has been tested in randomized human trials, in contrast to many "leaky gut" treatments that lack rigorous clinical validation (Leffler et al., 2015, Gastroenterology; PMID: 25683116).

KPV (lysine proline valine) is a C terminal tripeptide fragment of alpha melanocyte stimulating hormone (alpha MSH (Kannengiesser et al., 2008, Inflamm Bowel Dis; PMID: 18092346)). Despite being just three amino acids, it retains the anti inflammatory properties of the parent molecule while being more resistant to enzymatic degradation. It inhibits NF kB and MAP kinase inflammatory signaling and reduces pro inflammatory cytokine production in intestinal epithelial and immune cells (Dalmasso et al., 2008, Gastroenterology; PMID: 18061177). In mouse colitis models, oral KPV taken up through the PepT1 transporter reduced intestinal inflammation (Dalmasso et al., 2008, Gastroenterology; PMID: 18061177). One of KPV's most attractive properties is its potential for oral delivery (Dalmasso et al., 2008, Gastroenterology; PMID: 18061177). KPV is taken up by the intestinal peptide transporter PepT1, and oral KPV reduced colitis in mouse models, suggesting it may act locally on the inflamed intestine when taken orally (Dalmasso et al., 2008, Gastroenterology; PMID: 18061177). The evidence is primarily preclinical, though. Animal studies are encouraging, but human clinical trial data is limited.

Teduglutide (Gattex) represents one of the most successful peptide therapies for GI conditions. It is a GLP 2 analogue, and GLP 2 has the most potent intestinotrophic (intestinal growth promoting) properties of the proglucagon derived peptides (Goldschmidt et al., 2024, Expert Opin Pharmacother; PMID: 39588923). GLP 2 has trophic effects on small intestinal and colonic mucosa and enhances nutrient absorption (Kounatidis et al., 2022, Curr Nutr Rep; PMID: 35933503). Teduglutide is FDA approved for short bowel syndrome (SBS), a condition where surgical resection or disease has left insufficient intestinal length for adequate nutrient absorption (Kounatidis et al., 2022, Curr Nutr Rep; PMID: 35933503). In the Phase III STEPS trial, 63% of patients on teduglutide reduced their parenteral nutrition volume by at least 20%, versus 30% on placebo (Jeppesen et al., 2012, Gastroenterology; PMID: 22982184).

A few practical considerations for anyone exploring GI peptide therapy. First, GI symptoms require proper diagnostic evaluation before starting peptide therapy. Rule out celiac disease, IBD, infections, malignancy, and structural causes. Second, keep the evidence hierarchy in mind: teduglutide is approved with robust trial data, larazotide has mixed results from randomized trials, BPC 157 has extensive preclinical but limited human data, and KPV is primarily preclinical (Leffler et al., 2015, Gastroenterology; PMID: 25683116). This should inform clinical decision making and patient counseling. Third, dietary optimization (elimination of trigger foods, adequate fiber, pre and probiotic support), stress management, and sleep optimization should accompany any peptide protocol for GI health. And fourth, track symptoms systematically using validated GI symptom questionnaires, and consider intestinal permeability testing (lactulose and mannitol ratio or zonulin levels) before and after treatment when targeting barrier function.